Viking Therapeutics Inc Stock
€29.73
Your prediction
Viking Therapeutics Inc Stock
Pros and Cons of Viking Therapeutics Inc in the next few years
Pros
Cons
Performance of Viking Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | -4.370% | -11.348% | 2.535% | -39.238% | -24.113% | 666.108% | 459.056% |
| Ardelyx Inc. | -1.240% | -4.087% | 9.915% | 2.953% | -3.102% | 139.353% | -1.696% |
| Krystal Biotech | 0.080% | 1.055% | 5.319% | 4.821% | 16.426% | 136.267% | - |
| Evolus Inc | 0.850% | -3.279% | 11.321% | -49.573% | -43.810% | -18.621% | 111.091% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Evaluating the financials of Viking, a company operating in the Biotechnology and Medical Research industry, reveals a noteworthy, albeit challenging financial landscape. The financial statements indicate struggles with revenue generation and profitability, evident from consistent net losses over the past three years. However, the potential for innovation and advancements in biotechnology keeps the door open for future growth, given the right strategic decisions.
The financial health of Viking underscores a crucial juncture: while the company possesses a significant market capitalization of approximately $6.42 billion, it has yet to convert this potential into revenue, as indicated by a total revenue figure of zero in the income statements. With negative earnings per share, mounting losses, and a dwindling cash flow, questions arise about its operational viability without a shift in its current trajectory. Nevertheless, the company holds substantial assets and cash reserves which could support R&D efforts crucial for breakthroughs in biotechnology.
Market Capitalization: Viking's substantial market capitalization suggests confidence from investors and signals a strong foundational value. This capitalization can provide leverage for further investments or strategic partnerships.
Comments
News
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
On November 14, 2025, 5AM Venture Management, LLC, disclosed that it sold out its Viking Therapeutics stake, a move representing an estimated $5.02 million net position change.
According to a
This Is Why Royal Caribbean Is the Only Major Cruise Line Stock I Own
Until a few weeks ago, I was more than happy to own shares in all three of the major cruise line stocks. Royal Caribbean (NYSE: RCL) was my largest of the three positions, followed by Carnival
2 Monster Stocks in the Making
There's nothing wrong with investing in well-known, market-leading corporations. Many still have excellent prospects and robust underlying businesses. However, it's also worth considering smaller